GLP-1 drugs are “the most effective drugs we’ve ever invented for obesity treatment,” but they “aren’t going to cure the obesity epidemic,” says one public health expert.
Widespread usage of GLP-1 drugs will have a profound impact on the food industry, predicts Wegovy user and founder of Sweden Foodtech Johan Jörgensen.
New consumer research from Mattson into users of GLP-1 drugs indicates they want more protein, smaller portion sizes, and foods that soothe nausea and digestive discomfort.
GLP-1 drugs are “going to be a big disruptor for the food industry,” says Dr. Justin Shimek at California-based product innovation firm Mattson, which is expanding to the Midwest with the acquisition of Hyde Park Group.
Are GLP-1 drugs “an existential threat to the processed food industry,” as one academic recently told the New York Times, or are they creating new opportunities for companies to create new products or reposition existing ones?
Are GLP-1 drugs an ‘existential threat’ to the food industry or an opportunity for some creative thinking?
Consumers will look for foods and dietary supplements that naturally mimic the effects of GLP-1 drugs, predicts Bharat Vasan.
Sponsored
Sponsored post: The innovator’s dilemma: why agbioscience innovation must focus on the farmer first